Nomination for Ranking TOP - 100 CPhI Pharma Awards - Pharma Achievement 2020
TOP-100 Pharmaceuticals Companies CPhI Pharma Awards was awarded to Mumbai based Taj Pharmaceuticals Limited to Mr.Abhishek Singh, CEO of Taj Pharma Group (Indian Operations) and Best Enterprise award for Taj Pharmaceuticals Limited Pharma Focus Asia
- (1888PressRelease) June 04, 2020 - Mr. A.K.Singh CEO, Taj Pharmaceuticals was alwared TOP-100 Pharmaceuticals Companies CPhI Pharma Awards. Pharma Focus Asia Achievements-2020 Expert council conducts the annual research with the aim to select and encourage promising companies at the forefront of regional business.
Taj Pharmaceuticals has been selected as the nominee of TOP-100 CPhI Pharma Awards. Pharma Focus Asia Achievements-2020 register with presentation of the Best Enterprise award.
We are sure that in current situation for the winning companies such as Taj Pharmaceuticals it is very important to emphasize reputation and achievements, promote their institutions and attract new supplied across globe given the COVID 19 situation and shortage; The partners and investors will recognize all such attempts.
Taj Pharmaceuticals - Taj Group - Announced as a Winner at CPhI Pharma Awards 2020
Taj Pharmaceuticals has been named the winner in the Analysis, Testing, and Quality Control category at the prestigious CPhI Pharma Awards 2020.
The annual awards provide recognition to those who turn inspiration into innovation within the pharmaceutical industry.
Taj Pharmaceuticals’s win comes as a direct result of its efforts in pioneering and refining new approaches to demonstrate the bioequivalence of topical generic products in regulatory submissions.
Abhishek Kumar Singh, Director and CEO of Taj Pharmaceuticals, commented: “This award is a testament to Taj Pharmaceuticals’s depth of experience and integrity in the field of in vitro modeling and topical formulation development.
“By refining and automating these in vitro models Taj Pharmaceuticals has created a cost-effective route to demonstrating bioequivalence.”
Both the EMEA and FDA have recently recognized that the approval of topical generic products has been hampered by their demand to demonstrate bioequivalence in the clinic. These clinical trials are expensive and risky which has created a major barrier to generic entry.
Taj Pharmaceuticals has worked with the regulatory authorities to develop sophisticated in vitro models and robust statistical justification using multiple donors to demonstrate bioequivalence.
The company’s recent double-digit top-line growth can be attributed to the demand for these specialist services. The ultimate winner is the patient who can benefit from a more cost-effective topical therapy.
For more information on Taj Pharmaceuticals and its services, please visit: www.tajpharma.com
About Taj Pharma India
Taj Pharmaceuticals is the global leader in generics and one of the India’s top ten pharmaceutical companies. Taj Pharma India play a leading role in therapeutic areas such as cancer, virology and transplantation. The combined strengths of Taj Pharma generics and pharmaceuticals businesses, coupled with expertise in the emerging genetic sciences, equip us to develop integrated healthcare solutions and therapeutic approaches tailored to individual patients’ needs. Taj Pharmaceutical’s products and services address the entire healthcare spectrum, from screening for genetic risk factors, to preventing, diagnosing and treating disease, and monitoring the treatment response.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam